RY 169.88 -1.0542% SHOP 144.59 -0.959% TD 77.85 -0.1667% ENB 59.62 -0.5505% BN 78.53 -0.971% TRI 223.92 -0.2495% CNQ 47.03 -0.0213% CP 102.49 -0.5627% CNR 147.77 -0.8787% BMO 131.32 -0.0685% BNS 78.4 0.0255% CSU 4463.7002 0.6222% CM 90.42 0.6344% MFC 44.91 -1.3184% ATD 77.0 -0.7604% NGT 60.01 -0.4149% TRP 68.0 -2.2989% SU 56.965 -0.4282% WCN 260.14 -0.653% L 176.45 0.7135%
Last update at 2024-11-20T19:29:00Z
Eupraxia Pharmaceuticals Announces Pricing of Overnight Marketed Offering
Tue 12 Apr 22, 01:49 PMEupraxia Pharmaceuticals Announces Overnight Marketed Offering
Mon 11 Apr 22, 08:03 PMEupraxia Pharmaceuticals Inc. Announces Appointment of Bruce Cousins as President & CFO
Mon 03 May 21, 11:00 AMTMX Group Equity Financing Statistics - March 2021
Fri 09 Apr 21, 01:00 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -23.91722M | -23.36955M | -4.01064M | -7.24058M | -14.83301M |
| Minority interest | 0.66M | 0.38M | -0.45389M | -0.44045M | -0.37602M |
| Net income | -23.25937M | -22.98961M | -3.99720M | -7.17614M | -13.23198M |
| Selling general administrative | 5.53M | 8.41M | 1.27M | 3.01M | 7.54M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | - | - | - | - | - |
| Reconciled depreciation | 0.19M | 0.11M | 0.12M | 0.20M | 0.13M |
| Ebit | -23.20393M | -18.19966M | -2.24619M | -6.15853M | -11.88379M |
| Ebitda | -22.13558M | -21.96133M | -2.01220M | -5.57485M | -14.56501M |
| Depreciation and amortization | - | - | - | - | - |
| Non operating income net other | - | - | - | - | - |
| Operating income | -23.23561M | -20.96741M | -2.24619M | -6.15853M | -14.31472M |
| Other operating expenses | - | - | - | - | - |
| Interest expense | 1.59M | 1.30M | 1.88M | 1.46M | 0.14M |
| Tax provision | - | - | - | - | - |
| Interest income | 0.67M | 2.40M | 0.00043M | 0.01M | 0.00111M |
| Net interest income | -1.01904M | -1.23096M | -1.88121M | -1.45174M | -0.14107M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | - | - | - | - | - |
| Total revenue | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Total operating expenses | 23.20M | 18.68M | 2.25M | 6.16M | 14.31M |
| Cost of revenue | - | - | - | - | - |
| Total other income expense net | 0.31M | -3.46091M | 0.12M | 0.37M | -0.37722M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -23.91721M | -23.36955M | -4.01064M | -7.24058M | -14.83301M |
| Net income applicable to common shares | -23.25937M | -22.98961M | -3.99720M | -7.17614M | -13.23198M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 26.72M | 25.88M | 31.22M | 1.45M | 3.29M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.36M | - | - | - | - |
| Total liab | 25.55M | 13.02M | 10.84M | 23.12M | 21.42M |
| Total stockholder equity | 2.92M | 12.86M | 20.39M | -21.20976M | -17.69039M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 11.76M | - | 0.00501M | 6.94M | 6.80M |
| Common stock | 122.52M | 92.34M | 80.71M | 23.80M | 23.55M |
| Capital stock | 92.91M | 92.34M | 80.71M | 23.80M | 23.55M |
| Retained earnings | -139.11401M | -97.44614M | -74.18676M | -51.19716M | -47.19996M |
| Other liab | - | - | - | 0.38M | 0.50M |
| Good will | - | - | - | - | - |
| Other assets | 0.00000M | 0.00337M | 0.03M | - | - |
| Cash | 25.50M | 24.74M | 20.89M | 0.15M | 1.16M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 25.55M | 4.14M | 2.27M | 22.54M | 20.67M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | -11.72199M | - | - | 12.37M | 10.47M |
| Short term debt | 13.78M | 0.00000M | 0.00000M | 17.57M | 16.56M |
| Short long term debt | 10.40M | 0.11M | 0.09M | 12.52M | 11.63M |
| Short long term debt total | 13.78M | - | - | 0.20M | 0.25M |
| Other stockholder equity | 23.09M | 17.96M | 13.86M | - | - |
| Property plant equipment | - | 0.70M | 0.59M | 0.32M | 0.65M |
| Total current assets | 26.11M | 25.18M | 30.60M | 1.14M | 2.64M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 12.86M | 20.39M | -21.20976M | -17.69039M |
| Short term investments | - | 0.00000M | 9.01M | - | - |
| Net receivables | 0.25M | 0.12M | 0.43M | 0.62M | 1.35M |
| Long term debt | - | 10.30M | 9.26M | - | - |
| Inventory | 0.00000M | - | - | - | - |
| Accounts payable | - | - | - | - | - |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -3.56886M | - | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.00910M | - | - | - | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 0.61M | 0.70M | 0.62M | 0.32M | 0.65M |
| Capital lease obligations | 0.05M | 0.14M | 0.20M | 0.25M | 0.31M |
| Long term debt total | - | 10.37M | 9.40M | 0.20M | 0.25M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 9.01M | -9.00000M | -9.00000M | -9.00000M | -9.00000M |
| Change to liabilities | 1.78M | -0.46748M | 0.85M | 0.31M | 1.35M |
| Total cashflows from investing activities | 8.70M | -14.44982M | 0.02M | -1.89504M | -0.14186M |
| Net borrowings | -0.18518M | 12.08M | -0.39070M | 7.40M | 3.67M |
| Total cash from financing activities | 13.52M | 49.92M | -0.62664M | 7.40M | 5.30M |
| Change to operating activities | -0.02053M | 0.07M | 0.00291M | 0.03M | -0.04724M |
| Net income | -23.25937M | -22.98961M | -3.99720M | -7.17614M | -13.23198M |
| Change in cash | 3.84M | 20.74M | -1.00595M | 0.33M | -3.16668M |
| Begin period cash flow | 20.89M | 0.15M | 1.16M | 0.82M | 3.99M |
| End period cash flow | 24.74M | 20.89M | 0.15M | 1.16M | 0.82M |
| Total cash from operating activities | -18.77643M | -14.64163M | -0.40378M | -5.17101M | -8.32028M |
| Issuance of capital stock | 13.30M | 37.83M | - | - | 0.00000M |
| Depreciation | 0.19M | 0.11M | 0.12M | 0.20M | 0.13M |
| Other cashflows from investing activities | 9.01M | -5.01815M | -0.05669M | -1.88556M | -1.88556M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | 0.31M | 0.19M | 0.73M | 0.14M | -0.20858M |
| Sale purchase of stock | 13.71M | 37.83M | - | 0.00000M | 1.65M |
| Other cashflows from financing activities | - | 0.00000M | -0.23595M | -0.23595M | -0.08719M |
| Change to netincome | 2.22M | 8.45M | 1.89M | 1.32M | 3.69M |
| Capital expenditures | 0.31M | 0.43M | 0.43M | 0.00948M | 0.14M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 2.07M | -0.17626M | 1.56M | 0.48M | 1.10M |
| Stock based compensation | 2.02M | 4.21M | 0.23M | 0.54M | - |
| Other non cash items | 1.16M | 3.41M | 1.69M | 0.87M | 2.08M |
| Free cash flow | -19.08480M | -15.07330M | -0.40393M | -5.18049M | -8.46214M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to EBITDA (x) | |
|---|---|---|---|---|---|---|---|---|
| EPRX Eupraxia Pharmaceuticals Inc |
0.61 13.26% | 5.21 | - | - | - | 7.62 | -3.8823 | |
| FRX Fennec Pharmaceuticals Inc |
0.70 12.30% | 6.39 | 58.90 | 212.77 | 3.27 | 57.98 | 2.14 | 15.89 |
| MDNA Medicenna Therapeutics Corp |
-0.12 7.41% | 1.50 | - | 204.08 | - | 6.92 | -6.1093 | |
| ONC Oncolytics Biotech Inc |
-0.08 5.41% | 1.40 | - | - | - | 6.21 | -2.4457 | |
| TH Theratechnologies Inc. |
0.02 1.19% | 1.70 | - | 18.32 | 0.97 | 19.46 | 0.93 | 6.74 |
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
2067 Cadboro Bay Road, Victoria, BC, Canada, V8R 5G4
| Name | Title | Year Born |
|---|---|---|
| Dr. James A. Helliwell FRCPC, M.D. | CEO & Director | 1974 |
| Mr. Bruce G. Cousins CPA, C.A., CPA | Pres & CFO | 1961 |
| Dr. Amanda Malone Ph.D. | Chief Scientific Officer | 1981 |
| Mr. Paul Anthony Brennan B.Sc., M.Sc. | Chief Bus. Officer | NA |
| Mr. Bruce G. Cousins C.A., CPA | President & CFO | 1961 |
| Dr. Amanda Malone Ph.D. | Chief Scientific Officer & COO | 1981 |
| Mr. Paul Anthony Brennan B.Sc., M.Sc. | Chief Business Officer | NA |
| Dr. Mark M. Kowalski M.D., Ph.D. | Chief Medical Officer | 1955 |
| Dr. Rahul Sarugaser M.B.A., Ph.D. | Executive Vice President of Corporate Development | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...